Journal article
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
European urology oncology, Vol.6(5), pp.531-534
10/2023
DOI: 10.1016/j.euo.2023.06.011
PMID: 37468392
Abstract
Intravesical gemcitabine and docetaxel have comparable efficacy to bacillus Calmette-Guérin in patients with intermediate-risk non–muscle-invasive bladder cancer.
Adjuvant treatment with either single-agent chemotherapy or bacillus Calmette-Guérin (BCG) is recommended for patients with intermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC). In this multi-institutional retrospective review, we evaluated oncological outcomes for 182 patients with IR-NMIBC treated with BCG (n = 100) or intravesical sequential gemcitabine and docetaxel (Gem/Doce; n = 82). Median follow-up was 48.6 mo (interquartile range 24.9–70.9). No patient had a previous diagnosis of high-grade disease. Recurrence rates were similar in the two treatment groups (hazard ratio [HR] 1.06, 95% confidence interval [CI] 0.65–1.73; p = 0.8). Results were consistent after adjusting for International Bladder Cancer Group risk subgroups, use of single-instillation postoperative chemotherapy, use of blue light cystoscopy, and receipt of maintenance therapy (HR 0.88, 95% CI 0.47–1.64; p = 0.7). Similarly, there was no difference in the rate of stage/grade progression between the treatment groups (HR 0.66, 95% CI 0.21–2.12; p = 0.5). Rates of progression to muscle-invasive disease/metastasis (2.2%) and cancer-specific mortality (1.7%) were low in the cohort. Our results support the use of Gem/Doce as an alternative to BCG in patients with IR-NMIBC.
We compared cancer control outcomes for two different treatments for intermediate-risk non–muscle-invasive bladder cancer. Both treatments involve installation of a solution into the bladder that is left in place for approximately 2 hours. Our results show that a chemotherapy combination of docetaxel and gemcitabine is just as effective as the BCG (bacillus Calmette-Guérin) treatment traditionally used for this type of bladder cancer.
Details
- Title: Subtitle
- Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
- Creators
- Wei Shen Tan - The University of Texas MD Anderson Cancer CenterIan M. McElree - University of IowaFacundo Davaro - Moffitt Cancer CenterRyan L. Steinberg - University of IowaKelly Bree - The University of Texas MD Anderson Cancer CenterNeema Navai - The University of Texas MD Anderson Cancer CenterColin P. Dinney - The University of Texas MD Anderson Cancer CenterMichael A. O'Donnell - University of IowaRoger Li - Moffitt Cancer CenterAshish M. Kamat - The University of Texas MD Anderson Cancer CenterVignesh T. Packiam - University of Iowa
- Resource Type
- Journal article
- Publication Details
- European urology oncology, Vol.6(5), pp.531-534
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.euo.2023.06.011
- PMID
- 37468392
- ISSN
- 2588-9311
- eISSN
- 2588-9311
- Language
- English
- Electronic publication date
- 07/18/2023
- Date published
- 10/2023
- Academic Unit
- Urology
- Record Identifier
- 9984445624602771
Metrics
24 Record Views